The DOI matches its Crossref record.
CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole
Abstract
In vitro data on the metabolism of the antifungal voriconazole suggest that its pharmacokinetics might be influenced by the activity of CYP2C19, CYP2C9, and CYP3A. To elucidate the genetic influence of polymorphic enzymes on voriconazole metabolism, the authors pooled the pharmacokinetic data from 2 interaction studies in which 35 participants were enrolled according to their CYP2C19 genotype to receive a single 400‐mg oral dose of voriconazole. Nine participants were homozygous for CYP2C19*1/*1, 8 heterozygous for *1/*17, 11 heterozygous for*1/*2, 2 heterozygous for *2/*17, 4 homozygous for *2/*2, and 1 with a double mutation CYP2C19*2/*2*17. Nine (heterozygous) individuals were carriers of the CYP2C9*2 or *3 variant alleles. Twenty‐five participants did not express the CYP3A5 isozyme (*3/*3), whereas in 5 individuals, the *1/*3 combination was present (active enzyme). In addition, the CYP2D6 genotype and 2 variants of the drug transporter MDR1 (C3435T and G2677T) were determined. Multiple regression analysis of voriconazole apparent oral clearance revealed that 49% of its variance can be explained solely by the CYP2C19 polymorphism (P < .0001). Including the other polymorphisms into the regression model did not show any significant contribution. The number of variant CYP2C19 alleles therefore explains a substantial part of the wide variability of voriconazole pharmacokinetics, whereas the presence of functional CYP3A5 and the CYP2C9 genotype had no significant impact on voriconazole exposure. Some minor contribution results from the MDR1 C3435T genotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sibbing, D., Koch, W., Gebhard, D., Schuster, T., Braun, S., Stegherr, J., Morath, T., Schömig, A., von Beckerath, N., & Kastrati, A. (2010) · Circulation · doi:10.1161/circulationaha.109.885194 · Cited by 585
Moriyama, B., Obeng, A. O., Barbarino, J., Penzak, Sr., Henning, S., Scott, S., Agúndez, J., Wingard, Jr., McLeod, H., Klein, T., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.583 · Cited by 404
Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring
Dolton, M. J., Ray, J. E., Chen, S. C.-A., Ng, K., Pont, L. G., & McLachlan, A. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00626-12 · Cited by 290
Adverse interactions between antifungal azoles and vincristine: review and analysis of cases
Moriyama, B., Henning, S. A., Leung, J., Falade‐Nwulia, O., Jarosinski, P., Penzak, S. R., & Walsh, T. J. (2012) · Mycoses · doi:10.1111/j.1439-0507.2011.02158.x · Cited by 164
Fungal Infections in Transplant and Oncology Patients
Person, A. K., Kontoyiannis, D. P., & Alexander, B. D. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.11.013 · Cited by 33
Metadata
- Authors
- Weiss, J., ten Hoevel, M. M., Burhenne, J., Walter‐Sack, I., Hoffmann, M. M., Rengelshausen, J., Haefeli, W. E., & Mikus, G.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2009-02
- Volume
- 49
- Issue
- 2
- Pages
- 196-204
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2051816101
- Cited by
- 208
- References
- 0
- FWCI
- 10.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole. https://app.cochat.ai/papers/10.1177/0091270008327537
- The paper
- Weiss, J., ten Hoevel, M. M., Burhenne, J., Walter‐Sack, I., Hoffmann, M. M., Rengelshausen, J., Haefeli, W. E., & Mikus, G. (2009). CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270008327537
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.